Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration.
Curr Opin Ophthalmol
; 20(3): 223-5, 2009 May.
Article
em En
| MEDLINE
| ID: mdl-19367163
ABSTRACT
PURPOSE OF REVIEW To report the safety and efficacy of intravitreal injections for age-related macular degeneration (AMD). RECENT FINDINGS:
Injecting antivascular endothelial growth factor drugs into the vitreal cavity brings new hope to many AMD patients. Currently, several antivascular endothelial growth factor drugs such as pegaptanib, ranibizumab, and bevacizumab are used via the intravitreal route for neovascular AMD. However, these injections are not without ocular or systemic complications.SUMMARY:
Review of current literature suggests that intravitreal antivascular endothelial growth factor agents are generally a safe and effective treatment for neovascular AMD for up to 2-3 years. Presently, there is level I evidence to substantiate this conclusion for pegaptanib and ranibizumab, but not bevacizumab.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Inibidores da Angiogênese
/
Fator A de Crescimento do Endotélio Vascular
/
Degeneração Macular
Limite:
Humans
Idioma:
En
Ano de publicação:
2009
Tipo de documento:
Article